Graphic AR-V7 person

Oncotype DX AR-V7 Nucleus Detect® test

Putting AR-targeted therapies to the test

You’ve been diagnosed with late-stage metastatic castration-resistant prostate cancer (mCRPC), so now what? You have to choose an appropriate treatment. More specifically, you need to know whether your tumor will respond to androgen receptor (AR)-targeted therapies—such as enzalutamide or abiraterone acetate—or should you consider chemotherapy or other therapies? Your doctor has ordered the AR-V7 Nucleus Detect® test to help you find out.

This webinar explains what mCRPC is and how it is currently treated. It also explains the role of resistance to AR-targeted drugs on treatments, and how the AR-V7 Nucleus Detect test can help optimize your treatment selection.


The more you know about your tumor, the more targeted your treatment can be.

Just as every patient is different, so is every tumor. For instance, 20-40% of mCRPC patients start out resistant to AR-targeted treatments, and virtually all patients eventually become resistant, even after initially responding to AR-targeted treatments. Once a tumor is resistant to AR-targeted treatments, studies show that those treated with chemotherapy may be more likely to live longer .

The AR-V7 Nucleus Detect test gives you and your doctor important information about how your individual tumor will likely behave. Valuable insights include:

  • Whether or not you will benefit from AR-targeted therapies
  • When to transition from AR-targeted therapies to other therapies such as chemotherapy
  • Predictions on improved overall survival rates on AR-targeted therapies versus other treatments


Graph mCRPC



Reasons to get the AR-V7 Nucleus Detect test:

Icon ribbon

It gives patients with mCRPC predictive and prognostic insights into your tumor

Quickly and confidentally determine next steps to find the most approprite treatment to fight your challenging cancer

Icon plus and minus

It’s the first and only nuclear-localized test to identify patients who will not respond to AR-targeted therapy

Once your tumor is resistant, AR-targeted treatments stop providing benefits, and studies show you are substantially more likely to live longer when treated with chemotherapy or other therapies instead

Icon report

The test has been clinically validated and proven in a large group of patients from multiple studies

Studies show that many mCRPC patients could benefit from knowing their nuclear AR-V7 status

Is the AR-V7 Nucleus Detect test right for you?

You may be a candidate for the AR-V7 Nucleus Detect test if you:

  • Have a confirmed mCRPC diagnosis
  • Have received and failed AR-targeted therapy
  • Are considering additional AR-targeted therapies

NOTE: If you’ve been diagnosed early-stage localized prostate cancer, you may be eligible for the Oncotype DX Genomic Prostate Score® (GPSTM) test.

Learn how the AR-V7 Nucleus Detest testing process

What you can expect from the AR-V7 Nucleus Detect results

See FAQs about the AR-V7 Nucleus Detect test

AR-V7 Nucleus Detect test patients have $0 financial responsibility*

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Your cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your insurer can confirm if and how the AR-V7 Nucleus Detect test will be covered.

of AR-V7 Nucleus Detect test patients have a financial responsibility of <$100*

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patients with high-deductible plans may receive a bill for most or all the cost of the Oncotype DX AR-V7 Nucleus Detect test if they have not satisfied their deductible.†

Learn about costs, coverage, and how Exact Sciences can help

**The numbers cited are based on historical patient billing data from 1/02/2021 to 12/31/2021. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages patients to contact their insurer with questions about AR-V7 Nucleus Detect test coverage.